Imatinib-d8

• Description:

  Imatinib-d8 is a deuterium labeled Imatinib (STI571) . Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

• Product Name Alternative:

  STI571-d8; CGP-57148B-d8

• UNSPSC:

  12352005

• Target:

  Autophagy; Bcr-Abl; c-Kit; PDGFR; SARS-CoV

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection; Autophagy; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.88

• Solubility:

  10 mM in DMSO|DMSO : 12.5mg/mL (ultrasonic) |H2O : 10mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C (NC1=CC=C (C) C (NC2=NC=CC (C3=CC=CN=C3) =N2) =C1) C4=CC=C (CN5C ([2H]) ([2H]) C ([2H]) ([2H]) N (C) C ([2H]) ([2H]) C5 ([2H]) [2H]) C=C4

• Molecular Formula:

  C29H23D8N7O

• Molecular Weight:

  501.65

• References & Citations:

  [1]Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96 (3) :925-32.|[2]Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13 (11) :3363-9.|[3]Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90 (19) :8924‐8933. Published 2016 Sep 12.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  1092942-82-9